Extrovis AG and Dr. Reddy's Laboratories, along with its subsidiaries, announce the launch of Fluorouracil Cream 0.5%, an authorised generic and therapeutic equivalent of Carac (fluorouracil cream) 0.5%, in the US market, approved by the US Food and Drug Administration (FDA).
Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
“This generic product launch marks a key milestone in our commitment to increasing patient access and long-term value creation for the US healthcare system."
"Our partnership with Dr. Reddy’s helps to ensure that patients and healthcare providers in the United States have continued access to a high-quality and cost-effective product,” said Hans R. Kamma, CEO and Chief Strategy Officer of Extrovis AG.
“Dr. Reddy’s brings deep expertise in commercialisation and distribution within the US market,” added Raghavendra Rao PV, Chief Financial Officer of Extrovis AG.
“This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly.”
Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30 g tube for topical use only. Please click here to see the full prescribing information.